Key facts
- It has raised $60.0M; the latest was Early Stage VC ($60.0M) in Jan 2026.
- Notable investors include Fred Eshelman, Mark Gergen.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Breakthru Medicine
- ·The full record, as it builds
Funding rounds
No funding rounds for Breakthru Medicine are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Breakthru Medicine
Operator of a biotechnology company intended to develop oncology therapeutics. The company offers a portfolio of cancer therapeutic programs supported by platform-enabled discovery and multiple independent development programs, enabling patients to identify, validate, and advance treatments for unmet clinical needs in oncology.
- Sector
- Healthcare
- HQ
- Phoenix, AZ, United States
- Founded
- 2024
- Website
- breakthrumed.com/
- Ownership
- Privately Held (backing)
Breakthru Medicine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Breakthru Medicine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Breakthru Medicine in its N-PORT filings yet. We sweep new filings monthly.